Cancer Comments

 (S)-2-Amino-3-(3-phenacetylimidazol-4-yl) propanoic acid

This new compound has reproducibly been independently confirmed as effective against all neoplasms tested :

ATCC U-87 ( Human Astrocytoma, Glioblastoma Multiforme )
ATCC HEP G2 ( Hepatocellular Carcinoma )
ATCC A-375 (Human Malignant Melanoma)

The Science... in detail (link)

This compound does not exhibit inhibition of normal 'healthy' B cells (D8 LCL B cells) - at concentrations used for inhibition of cancer.

This compound kills cancer cells.

Mechanism is consistent with induction of apoptosis - in neoplastic cells.

• A novel small molecule, alpha amino acid, antineoplastic - no demonstrated toxicity to 'healthy tissue'.

• No anticipated 'side-effects' (e.g. 'chemo-brain', hair-loss, hypernatremia, gastro-intestinal upset, nausea, somnolence).

• Wide therapeutic margin.

• Possible primary therapy, adjuvant therapy,  'compassionate use' therapy, possible prophylactic/maintenance therapy.

• Excellent likelihood for good stability (and thus long shelf life).

• Ease of use and administration - with oral dosing possible.

•Low cost of goods.

•Antibiotic properties.

•New 'reagent' - opens possibilities for all science.

•Possible nutritional supplement usage.

• Rapid inhibition of difficult to treat cancer cell lines.
• Reproducible cell viability/dose response curves.
• Mechanism consistent with activation of apoptotic pathway.
• Physico-chemical properties consistent with high oral absorption and BBB (Blood-brain barrier) permeability.
• Pharmacokinetics, ADME (Absorption, Distribution, Metabolism, Excretion), likely simple and efficient.
• Metabolism most probably through decarboxylation.

Finances are needed to finish the 'approval process' for this antineoplastic NCE:
CRO toxicology confirmation, IND/NDA filing with FDA, human clinical trials.
This is (and has been) ready! 



Regards,

Dennis Wright
drwright442000@yahoo.com

Hope... And Reality

 Several items to consider:

1.)  Currently, cancer victims who are refractile to chemotherapy and radiation therapy have limited options - (palliative care). 
This fact makes moot the argument to aggressively pursue treatment - the side effects are as detrimental as the disease.

*****

2.)   Independent testing has confirmed utility with difficult to treat cancer cell lines (U-87 [Astrocytoma, Glioblastoma Multiforme], HEP G2 [Hepatocellular Carcinoma], A 375 [Human Malignant Melanoma]).
Animal testing (mice), has shown no adverse effects - at concentrations thousands of times higher than used for in vitro testing.

*****

3.)   The benefits of commercial development of the NCE's outweigh all perceived risks. 
Independent verification of claims is a straightforward process... There is no downside. In addition to the preferred usage with oncology, these compounds are new chemical entities - specifically - novel alpha amino acids - which have demonstrated antibiotic utility.

*****

4.)   At present, the state-of-the-art regimen for aggressive cancer treatment involve combinations of  surgical excision, chemotherapy, radiation therapy. 
The compound, (S)-2-Amino-3-(3-phenylacetylimidazol-4-yl)propanoic acid,  may eliminate the need for all of these.

*****

5.)  There are 208 separate and distinct cancers. 

The above points suggest a new compound which has potential for therapeutic treatment (primary, combination, adjuvant, prophylactic) of most, if not all, cancers - with no adverse side effects.

*****

The Science

• A novel small molecule, alpha amino acid, antineoplastic - no demonstrated toxicity to 'healthy tissue'.

• No anticipated 'side-effects' (e.g. hair-loss, hypernatremia, gastro-intestinal upset, nausea, somnolence).

• Wide therapeutic margin.

• Possible primary therapy, combination therapy, adjuvant therapy,  'compassionate use' therapy, possible prophylactic/maintenance therapy.

• Excellent likelihood for good stability (and thus long shelf life).

• Ease of use and administration - with oral dosing possible.

•Low cost of goods.

•Antibiotic properties.

•New 'reagent' - opens possibilities for all science.

•Possible nutritional supplement usage.

•Demonstrated mechanism consistent with apoptotic pathway activation - in neoplastic cells.

*****

By activating the apoptosis pathway in a cancer cell leading to the cell death, this compound can be used to treat cancer of any type or origin, such as but not limited to adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma or teratocarcinoma, or the cancer of adrenal gland, bladder, bone, bone marrow, brain, breast, cervix, gall bladder, ganglia, gastrointestinal tract, heart, kidney, liver, lung, muscle, ovary, pancreas, parathyroid, penis, prostate, salivary glands, skin, spleen, testis, thymus, thyroid or uterus.

*****

The science is independently confirmed, reproducible and undisputed... the impediment for this cure is  funding to advance the approval process (CRO toxicology, IND/NDA, human clinical trials). And, yes, it is rewarding to know this compound will save lives.

Regards,

Dennis Wright
drwright442000@yahoo.com

Mesothelioma... guest article

What is Mesothelioma?

Unlike other forms of cancer, Mesothelioma, is not as widely known.  Between 2000 and 3000 people are diagnosed with this rare form of cancer each year in the United States.  It is known to be a silent killer because it is so difficult to diagnose.  Many of those who are affected generally don’t experience symptoms for 20 to 50 years after their initial exposure.  The latency period can last several decades; and, by the time symptoms are apparent, it is often times too late.  Since the symptoms related to mesothelioma are very similar to those of other conditions, it is often times misdiagnosed or overlooked.

As previously mentioned, the latency period causes many potential problems for accurate diagnosis.  The reason for this latency period is due to the fact that many people were exposed to asbestos before the 80’s.  Asbestos laced products were heavily used in the military, construction, automobile industry, asbestos mining and processing plants, as well as residential areas.  Mesothelioma is primarily found in the lungs and/or abdomen.  In some instances, the likelihood for cancer in other areas of the body can increase.  Asbestos exposure occurs when microscopic asbestos fibers are inhaled and ingested.  These fibers then attach to the mesothelial lining of the lungs and, over time, can develop into cancerous tumors. 

For those who have been diagnosed with Mesothelioma, the prognosis is rather grave.  There are various factors that impact the mesothelioma prognosis; for example, how early it is detected, the type of mesothelioma, the overall health of the person, size/location of the tumor, and the stage of mesothelioma.  There are four stages of mesothelioma; Stage 1 describes the tumor as confined and does not involve the lymph nodes, Stage 2 has the tumor confined and the lymph nodes are involved, Stage 3 the tumor has penetrate past its confinement and involve the lymph nodes, Stage 4 is the most advance and least optimistic with the tumor fully metastasized into other parts of the body.

Unfortunately, there is no cure for mesothelioma; however, there are steps that can be taken in hopes to improve the prognosis associated with this cancer.  Many of those affected have undergone chemotherapy, radiation therapy, clinical trials, and even surgery.

We offer a variety of resources for mesothelioma patients and their families at The Mesothelioma Center.  Our wonderful Patient Advocates are available to assist with any questions you may have.  We also offer a Doctor Match program in which we are able to introduce you to doctors and suggest treatment centers for your specific diagnosis.  If you would like more information about mesothelioma, asbestos, or other asbestos related disease please feel free to visit: http://www.asbestos.com. http://twitter.com/TheMesoCenter http://www.facebook.com/themesocenter

(S)-2-Amino-3-(3-phenylacetylimadazol-4-yl)propanoic acid

• Rapid inhibition of difficult to treat cancer cell lines.
• Reproducible cell viability/dose response curves.
• Mechanism consistent with activation of apoptotic pathway.
• Physico-chemical properties consistent with high oral absorption and BBB (Blood-brain barrier) permeability.
• Pharmacokinetics, ADME (Absorption, Distribution, Metabolism, Excretion), likely simple and efficient.
• Metabolism most probably through decarboxylation.

This new chemical entity (NCE) has been independently confirmed as effective against U-87 cell line (brain cancer, anaplastic astrocytoma - glioblastoma multiforme), HEP G2 cell line (liver cancer, hepatocellular carcinoma), A 375 cell line (human malignant melanoma). A wide therapeutic margin with no inhibition of D8 LCL 'B' cells (control - 'normal' bone marrow) - at concentrations used to inhibit neoplasms. There are 208 individual types of cancer - this compound is effective against all three types listed above and will most probably be effective against the remaining 205.

CRO toxicology, pre-IND meeting with FDA, human clinical trials (Phase I or Phase I/II hybrid) - as soon as $$$ are available. Let's save lives!
Contact me if you can be of assistance with finances to expedite this process. Thank you.

Regards,

Dennis Wright
drwright442000@yahoo.com




Metastasis

Advancing the 'state of the art'...

Currently, I am sourcing financing for toxicology testing and human clinical trials - for the new chemical entity, (S)-2-Amino-3-(3-phenylacetylimidazol-4-yl)propanoic acid. The anticipated timeline, here in the USA, will involve a complete toxicology study by a CRO (contract research organization), a pre-IND meeting with the FDA and subsequent human clinical trials (Phase I or a Phase I/II hybrid). If I can find sufficient finances soon - then it is possible to be in human clinical trials as soon as toxicology data is available (approximately six months or less). I anticipate early FDA approval - once the compound has been independently confirmed as 'non-toxic' to healthy tissue. This compound has a wide therapeutic margin and I anticipate utility against most, if not all, neoplasms. Antibiotic indications have also been demonstrated.

I do not concern myself with the 'politics' of pharmaceutical empires, rather, my efforts are directed at advancing the 'state of the art'. The science is undisputed... the impediment, at present, is securing adequate finances to advance the 'process'. And, yes, it is rewarding to know this compound will save lives.

Cancer Scientist Dennis Wright (Applied Molecular Biologist, Biochemist, Chemical Engineer)

Most if not all of us have had at least one member of our immediate or extended family struck down by the insidious disease known as cancer.  We have been accustomed to organizations raising funds to promote cancer research but we have been similarly accustomed to never hearing that a cure has been discovered.  Cancer treatments to date all seem to follow one of three traditional courses; surgery to cut the tumor out, radiation to attempt to burn it into submission, or chemotherapy to poison the offending cells.  Recently, there has been some scientific/medical discussion about more targeted therapies and about drugs that may hold off the rapidly regeneration of cancer cells to extend one's life expectancy.

Mr. Wright has been intellectualizing his thoughts and concepts for a new cancer cure for over 5 years.  He took those thoughts into his lab over 3 years ago and invented a completely new class of alpha amino acids.  The resulting compound was successfully tested in Wright's lab against brain cancer cell lines, causing an apoptotic cascade (essentially causing the cancer cells to commit suicide).  Thereafter he did dosing experiments on mice and found that doses thousands of times higher than those used to stop the cancer cells, were still not toxic to mice.